CG Oncology Inc.
NASDAQTotal Valuation
CG Oncology Inc. carries a market capitalization of 6.59B, placing it among publicly traded companies globally. Its enterprise value stands at 5.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.59B |
| Enterprise Value | 5.25B |
Share Statistics
CG Oncology Inc. currently has 88.31M shares outstanding.
| Shares Outstanding | 88.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 948.58, and the price-to-book ratio stands at 6.10.
| PE Ratio | N/A |
| PS Ratio | 948.58 |
| PB Ratio | 6.10 |
| P/TBV Ratio | 6.16 |
| P/FCF Ratio | -33.27 |
| P/OCF Ratio | -33.10 |
Enterprise Valuation
| EV / Sales | 843.72 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
CG Oncology Inc. maintains a current ratio of 22.22, meaning it holds 22.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 22.22 |
| Quick Ratio | 21.78 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -26.41 |
| Return on Assets (ROA) | -25.11 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 23.00 |
Stock Price Statistics
CG Oncology Inc.'s stock has gained approximately 141.33807% over the past 52 weeks. The 50-day moving average sits at 73.62, while the 200-day moving average is 60.93.
| Beta (5Y) | N/A |
| 52-Week Price Change | 141.33807% |
| 50-Day Moving Average | 73.62 |
| 200-Day Moving Average | 60.93 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CG Oncology Inc. generated 6.23M in revenue and converted that into -224.37M in net income, yielding earnings per share of -2.70. EBITDA reached -249.66M, while operating income came in at -252.62M.
| Revenue | 6.23M |
| Gross Profit | -5.31M |
| Operating Income | -252.62M |
| Pretax Income | -224.37M |
| Net Income | -224.37M |
| EBITDA | -249.66M |
| EBIT | -252.62M |
| Earnings Per Share (EPS) | -2.70 |
Balance Sheet
CG Oncology Inc. holds 1.03B in cash and equivalents against 8.82M in total debt, resulting in a net debt position of -16.64M. Total book value stands at 1.03B, with working capital of 1.00B providing operational flexibility.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 8.82M |
| Net Debt | -16.64M |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 11.65 |
| Working Capital | 1.00B |
Cash Flow
CG Oncology Inc. produced -178.47M in operating cash flow over the past twelve months. After subtracting -876,000.00 in capital expenditures, free cash flow totaled -179.34M - equivalent to -2.16 per share.
| Operating Cash Flow | -178.47M |
| Capital Expenditures | -876,000.00 |
| Free Cash Flow | -179.34M |
| FCF Per Share | -2.16 |
Margins
CG Oncology Inc. operates with a gross margin of -85.20, reflecting its pricing power and cost economics. The operating margin of -4,056.18 and net profit margin of -3,602.68 provide insight into operational efficiency.
| Gross Margin | -85.20 |
| Operating Margin | -4,056.18 |
| Pretax Margin | -3,602.68 |
| Profit Margin | -3,602.68 |
| EBITDA Margin | -4,008.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.74 |
| FCF Yield | -3.01 |
Scores
CG Oncology Inc. posts an Altman Z-Score of 66.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 66.26 |